AGEN Agenus Inc. - Common Stock
NASDAQ · Biotechnology · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Ago 7, 2026AGEN Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
AGEN Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
| Data ex | Desdobramento | Tipo |
|---|---|---|
| 12 de Abril de 2024 | 1-for-20 | Reverso |
| 26 de Abril de 2023 | 1019-for-1000 | Para frente |
| 3 de Outubro de 2011 | 1-for-6 | Reverso |
Sobre Agenus Inc. - Common Stock Visão geral da empresa da Wikipedia
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
History
Agenus (formerly Antigenics Inc.) was founded in 1994 by Garo H. Armen and Pramod K. Srivastava. The company has pioneered immunotherapies, including heat shock protein-based cancer vaccines, a program that has developed into its Prophage Series of personalized anti-cancer vaccines. Antigenics became a public company in February 2000 on the NASDAQ exchange with the ticker symbol AGEN. In 2000 Agenus acquired Aquila Biopharmaceuticals and a year later it acquired Aronex Pharmaceuticals. In February 2014 the company acquired a European firm, 4-Antibody, along with their portfolio of checkpoint modulators (CPMs) and a platform (Retrocyte Display® technology) to rapidly and efficiently discover new antibodies.
In October 2013, Agenus CEO Garo Armen issued a press release revealing that after an 18-month follow up on the RTS,S Malaria vaccine using QS21-Stimulon®, it was working well enough to support a regulatory filing in 2014. This was the first proof of the efficacy of Agenus's patented "QS-21 Stimulon" adjuvant
In April 2014, Agenus signed a deal with Merck potentially worth $100 million. Under the terms of that deal, Agenus is using its proprietary Retrocyte Display technology to discover antibodies against a pair of undisclosed checkpoint targets for the treatment of cancer. Agenus has advanced two of its own CPM candidates into early drug development and the company is planning to advance several more antibodies in clinical trials.
Today, Agenus is focused on developing a range of immuno-oncology products, including the Prophage vaccines, multiple checkpoint modulators (also known as checkpoint inhibitors or checkpoint antibodies) and its QS21-Stimulon adjuvant. The company's personalized, heat shock protein-based vaccines are in Phase 2 studies. The QS-21 Stimulon adjuvant platform is partnered with GlaxoSmithKline and Janssen. Several of those collaborations involve Phase 3 trials. Altogether, the company and its partners are sponsoring approximately 20 clinical trials of Agenus products.
In August 2023, Agenus announced a strategic restructuring to prioritize its botensilimab and balstilimab (BOT/BAL) clinical programs. The plan included a 25% reduction in its workforce (approximately 85 positions) and the temporary suspension of most preclinical and clinical programs not related to the BOT/BAL combination. The company stated the reorganization was intended to reduce annual operating expenses by approximately $40 million.
In 2025, Agenus sold their CDMO business to Zydus Lifesciences including their two biologics manufacturing sites in Emeryville and Berkeley. In addition, they would partner with Zydus to commercialize their molecules in India.
Key partners and deals
In April 2014, Agenus announced a collaboration and licensing agreement with Merck. The collaboration involved the discovery and development of therapeutic antibodies to two undisclosed Merck checkpoint targets, both thought to be relevant for cancer treatment, in addition to Agenus using its proprietary Retrocyte Display® platform to discover and optimize antibodies against the targets.
In February 2014, Agenus acquired European biotechnology firm 4-Antibody, along with its Retrocyte Display technology and a portfolio of checkpoint modulator antibody candidates .
In March 2012, GlaxoSmithKline acquired two extra rights in the two firms' agreement to use Agenus' QS-21 Stimulon adjuvant. The rights give GSK the first right in negotiation of purchase of Agenus or their assets, the rights expired in 2017 after five years had lapsed.
In June 2025, Agenus entered into a strategic collaboration with Zydus Lifesciences valued at up to $141 million. Under the agreement, Agenus transferred its biologics manufacturing facilities in Emeryville and Berkeley, California, to a new Zydus subsidiary, Zylidac Bio LLC, for an upfront payment of $75 million. The deal also included a $16 million equity investment by Zydus in Agenus common stock and up to $50 million in potential milestone payments. Additionally, Zydus obtained exclusive rights to develop and commercialize the botensilimab and balstilimab (BOT/BAL) combination therapy in India and Sri Lanka, with Agenus eligible for a 5% royalty on net sales. The transaction was formally closed in January 2026.
Product descriptions
Checkpoint modulators (CPMs) interfere with cancers’ ability to “hijack” natural immune defense systems. To protect the body against disease, but without attacking healthy cells, the immune system uses multiple “checkpoint” systems. Some checkpoints stimulate immune responses while others inhibit them. Cancer cells can evolve means to evade checkpoints, and CPMs can reverse that effect, helping the immune system better fight the cancer.
Agenus has programs targeting the checkpoint modulators GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company is expanding that portfolio by using a proprietary process to generate fully human therapeutic antibody drug candidates. The platform is a high-throughput approach incorporating IgG format human antibody libraries expressed in mammalian B-lineage cells.
The Prophage series of patient-specific cancer vaccine candidates can also enhance the immune system's response to tumors. Because each cancer is unique, the vaccine is derived from the patient's own tumor sample. To process these samples, Agenus has established a multi-product "good manufacturing practices" facility, which has already helped process over 1,000 tumor samples from across the globe.
The company's QS-21 Stimulon® adjuvant platform strengthens and broadens immune responses to antigens on cancers or foreign invaders’ surfaces. Agenus has multiple partnerships around this product to study its effects with vaccines for diseases including Alzheimer's, melanoma, and malaria. In October 2013, GlaxoSmithKline and Agenus announced positive data from an 18-month follow-up of GSK's RTS,S malaria vaccine with QS21-Stimulon. GSK stated that the treatment was working well enough to support a regulatory filing. RTS,S is the most advanced vaccine for malaria in development.
Agenus is the sole US-manufacturer of a patented and FDA-approved triterpene glycoside extract known as (QS-21, Matrix M), which is a key component in the manufacturing of the Oxford–AstraZeneca COVID-19 as well as the Novavax COVID-19 vaccines. Supplies are tightly controlled, and the US has invoked the US Defence Production Act to preserve vaccine raw materials for its own companies.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | AGEN | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/E (TTM) | 2.8média 5A ≈-144.8 | ≈-144.8 | · | · | |
| P/S (TTM) | 2.7 | · | 6.9 | Subvalorizado | |
| P/B (MRQ) | -1.8 | · | · | · | |
| EV / EBITDA | -16.7 | · | · | · | |
| Preço / FCF (TTM) | -3.6 | · | · | · | |
| Preço / Fluxo de Caixa (TTM) | -3.6 | · | · | · | |
| EV / Revenue (EV / Receita) | 3.0 | · | · | · | |
| EV / FCF | -4.4 | · | · | · | |
| Preço / Valor Patrimonial Tangível (MRQ) | -1.8 | · | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | AGEN | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Margem Operacional (TTM) | 27.3%média 5A ≈-82.1% | ≈-82.1% | -123.1% | Primeira linha | |
| EBITDA Margin (Margem EBITDA) | -17.7%média 5A ≈-82.1% | ≈-82.1% | -123.1% | Primeira linha | |
| Pretax Margin (Margem de Impostos Pré-Tributação) | -2.7% | · | -72.9% | Primeira linha | |
| Margem de Lucro Líquido (TTM) | 69.3%média 5A ≈-127.4% | ≈-127.4% | -150.6% | Primeira linha | |
| ROA (TTM) | 51.4%média 5A ≈-43.8% | ≈-43.8% | -38.5% | Primeira linha | |
| ROE (TTM) | -33.2%média 5A ≈416.3% | ≈416.3% | -38.3% | Primeira linha | |
| ROIC | 8.9% | · | -20.5% | Primeira linha |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | AGEN | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido (MRQ) | -0.2média 5A ≈-0.0 | ≈-0.0 | 0.1 | Baixa dívida | |
| Índice de liquidez corrente (MRQ) | 0.3média 5A ≈0.9 | ≈0.9 | 5.4 | Baixa liquidez | |
| Quick Ratio (Índice de Liquidez Seca) | 0.0média 5A ≈0.7 | ≈0.7 | 5.1 | Baixa liquidez | |
| Long-Term Debt / Equity (Dívida de Longo Prazo / Patrimônio Líquido) | 0.0média 5A ≈-0.0 | ≈-0.0 | 0.0 | Baixa dívida |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | AGEN | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | 10.4%média 5A ≈40.9% | ≈40.9% | · | · | |
| Revenue CAGR 3Y (CAGR Receita 3A) | 5.2%média 5A ≈-1.1% | ≈-1.1% | · | · | |
| Revenue CAGR 5Y (CAGR Receita 5A) | 5.3% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
| Métrica | Tendência de 5 anos | AGEN | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Asset Turnover (Giro do Ativo) | 0.5média 5A ≈0.5 | ≈0.5 | 0.4 | Primeira linha | |
| Receivables Turnover (Giro de Contas a Receber) | 102.1média 5A ≈77.6 | ≈77.6 | 4.5 | Primeira linha | |
| Revenue / Employee (Receita anual ÷ funcionários (número de funcionários reportado, yfinance). Derivado — não é um conceito SEC-XBRL armazenado.) | ≈$1.4M | · | · | · |
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | Ago 10, 2026 | $-0.01 | $0.05 | -119.6% |
| 31 de Março de 2026 | Mai 11, 2026 | $0.00 | $2.14 | -100.0% |
| 31 de Dezembro de 2025 | $-0.31 | $-1.07 | 71.1% | |
| 30 de Setembro de 2025 | $1.94 | $2.02 | -3.9% | |
| 30 de Junho de 2025 | $-1.00 | $1.38 | -172.4% | |
| 31 de Março de 2025 | $-1.03 | $-1.69 | 39.0% | |
| 31 de Dezembro de 2024 | $-2.04 | $-2.59 | 21.3% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $114M | $103M | $156M | $98M | $296M | $88M | $150M | $37M | $43M | $23M | $25M | $7M | |
| Cost of Revenue | $1M | $486.0K | $3M | $11M | $3M | $2M | · | · | · | · | · | $0 | |
| R&D Expense | $79M | $156M | $235M | $187M | $179M | $143M | $168M | $125M | $116M | $95M | $70M | $22M | |
| SG&A Expense | $54M | $72M | $79M | $81M | $76M | $59M | $46M | $37M | $34M | $33M | $28M | $21M | |
| Operating Income | $-20M | $-120M | $-160M | $-179M | $26M | $-117M | $-70M | $-124M | $-104M | $-107M | $-81M | $-43M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Interest Income | $345.0K | $3M | $6M | $2M | · | · | · | · | · | · | · | · | |
| Other Non-op | $72M | $6M | $37.0K | $11M | $5M | $-2M | $28.0K | $-2M | $2M | $-2M | $-6M | $2M | |
| Pretax Income | $-3M | $-232M | $-257M | · | · | · | · | · | $-121M | $-127M | $-93M | $-42M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $-5M | $0 | |
| Net Income | $-3M | $-232M | $-257M | $-231M | $-29M | $-183M | $-112M | · | $-121M | $-127M | $-88M | $-42M | |
| EPS (Basic) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 | · | · | · | · | · | · | |
| EPS (Diluted) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 | · | · | · | · | · | · | |
| Shares (Basic) | 29,734,000 | 21,473,000 | 17,894,000 | 14,087,000 | 228,919 | 172,504 | · | · | · | · | · | · | |
| Shares (Diluted) | 29,734,000 | 21,473,000 | 17,894,000 | 14,087,000 | 228,919 | 172,504 | · | · | · | · | · | · | |
| EBITDA | $-20M | $-120M | $-160M | $-179M | $26M | $-117M | $-70M | $-124M | $-104M | $-107M | $-81M | · |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3M | $40M | $76M | $179M | $292M | $100M | $62M | $53M | $60M | $71M | $137M | $26M | |
| Short-term Investments | · | · | · | $15M | $15M | · | · | · | · | $5M | $35M | $15M | |
| Receivables | $2M | $407.0K | $26M | $3M | $2M | $1M | $16M | $938.0K | $1M | $11M | $10M | $463.0K | |
| Inventory | · | · | · | · | · | · | $0 | $55.0K | $79.5K | $88.2K | $88.2K | $95.7K | |
| Prepaid Expense | $785.0K | $2M | $8M | $14M | $20M | $11M | $7M | $19M | $11M | $3M | $2M | $1M | |
| Other Current Assets | $1M | $2M | $2M | $3M | $3M | $2M | $1M | $1M | $1M | $838.5K | $582.3K | $640.0K | |
| Current Assets | $133M | $46M | $112M | $213M | $332M | $114M | $87M | $75M | $74M | $91M | $184M | $43M | |
| PP&E (Net) | $15M | $120M | $133M | $133M | $60M | $27M | $26M | $25M | $26M | $26M | $15M | $6M | |
| PP&E (Gross) | $63M | $193M | $195M | $187M | $111M | $74M | $69M | $63M | $60M | $57M | $45M | $34M | |
| Accum. Depreciation | $47M | $73M | $62M | $54M | $51M | $47M | $43M | $38M | $34M | $31M | $29M | $28M | |
| Goodwill | $24M | $24M | $25M | $25M | $25M | $25M | $23M | $23M | $23M | $22M | $23M | $18M | |
| Intangibles | $3M | $3M | $4M | $6M | $8M | $11M | $11M | $12M | $14M | $16M | $19M | $7M | |
| Other Non-current Assets | $3M | $6M | $9M | $4M | $10M | $4M | $1M | $1M | $1M | $1M | $1M | $1M | |
| Total Assets | $227M | $226M | $314M | $414M | $466M | $215M | $155M | $136M | $138M | $157M | $242M | $75M | |
| Accounts Payable | $83M | $61M | $61M | $41M | $30M | $17M | $14M | $14M | $8M | $5M | $4M | $2M | |
| Accrued Liabilities | $34M | $35M | $45M | $38M | $42M | $29M | $31M | $25M | $22M | $28M | $14M | $6M | |
| Current Liabilities | $323M | $221M | $256M | $189M | $157M | $130M | $122M | $68M | $56M | $41M | $29M | $9M | |
| Capital Leases | $10M | $55M | $63M | $63M | $42M | $34M | $8M | · | · | · | · | · | |
| Other Non-current Liabilities | $259.0K | $738.0K | $5M | $15M | $2M | $2M | $4M | $3M | $3M | $5M | $8M | $3M | |
| Long-term Debt | $45M | $33M | $13M | $13M | $14M | $20M | $14M | $13M | $163M | $131M | $114M | $6M | |
| Total Debt | $45M | $33M | $13M | $13M | $14M | $20M | $14M | $13M | $163M | $131M | $114M | · | |
| Common Stock | $353.0K | $236.0K | $197.0K | $3M | $3M | $2M | $1M | $1M | $1M | $877.9K | $863.9K | $627.2K | |
| Paid-in Capital | $1.91B | $1.86B | $1.80B | $1.64B | $1.52B | $1.26B | $1.06B | $1.01B | $952M | $867M | $851M | $716M | |
| Retained Earnings | $-2.18B | $-2.18B | $-1.96B | $-1.71B | $-1.49B | $-1.47B | $-1.28B | $-1.18B | $-1.03B | $-905M | $-779M | $-691M | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| AOCI | $-439.0K | $-1M | $-955.0K | $915.0K | $1M | $3M | $-1M | $-2M | $-2M | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $-271M | $-326M | $-160M | $-61M | $34M | $-204M | $-225M | $-172M | $-76M | $-39M | $71M | $23M | |
| Liabilities + Equity | $227M | $226M | $314M | $414M | $466M | $215M | $155M | $136M | $138M | $157M | $242M | $75M | |
| Shares Outstanding | 35,320,397 | 23,634,670 | 19,718,662 | · | · | · | · | · | · | · | · | · |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $13M | $14M | $7M | $7M | $7M | $7M | $6M | $6M | $5M | $2M | $2M | |
| Stock-based Comp | $14M | $17M | $23M | $18M | $20M | $10M | $10M | $8M | $12M | $13M | $7M | $5M | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | · | $-5M | · | |
| Amort. of Intangibles | $300.0K | $500.0K | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $462.0K | |
| Operating Cash Flow | $-77M | $-158M | $-224M | $-175M | $10M | $-139M | $-19M | $-131M | $-94M | $-80M | $-47M | $-38M | |
| CapEx | $6.0K | $576.0K | $10M | $53M | $34M | $3M | $5M | $4M | $3M | $13M | $4M | $3M | |
| Investing Cash Flow | $1M | $27.0K | $3M | $-34M | $-43M | $-4M | $-5M | $-4M | $2M | $18M | · | $-17M | |
| Debt Issued | · | · | · | · | · | $6M | · | · | $15M | · | $109M | · | |
| Net Debt Issued | $-2M | · | · | · | · | $6M | · | · | $15M | · | $109M | · | |
| Financing Cash Flow | $37M | $123M | $120M | $96M | $225M | $184M | $31M | $128M | $81M | $-2M | · | $53M | |
| Net Change in Cash | $-39M | $-36M | $-102M | $-113M | $192M | $41M | $9M | $-7M | $-11M | $-65M | $111M | $-2M | |
| Free Cash Flow | $-77M | $-159M | $-234M | $-228M | $-24M | $-143M | $-23M | $-135M | $-97M | $-92M | $-51M | · |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% | -133.0% | -46.7% | -336.6% | -242.1% | -476.1% | -325.2% | · | |
| Net Margin | -2.7% | -224.5% | -164.7% | -235.3% | -9.7% | · | · | · | -281.5% | -562.6% | -354.1% | · | |
| Pretax Margin | -2.7% | · | · | · | · | · | · | · | -281.5% | -562.6% | -375.8% | · | |
| EBITDA Margin | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% | -133.0% | -46.7% | -336.6% | -242.1% | -476.1% | -325.2% | · | |
| ROA | -1.4% | -86.0% | -70.8% | -52.4% | -8.4% | · | · | · | -81.7% | -63.6% | -55.5% | · | |
| ROE | 1.0% | 95.5% | 232.3% | 1718.9% | 34.0% | · | · | · | 210.0% | -803.7% | -187.5% | · | |
| ROIC | 8.9% | · | · | · | · | · | · | · | -119.0% | -117.4% | -41.1% | · |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | 0.2 | 0.4 | 1.1 | 2.1 | 0.9 | 0.7 | 1.1 | 1.3 | 2.2 | 6.4 | · | |
| Quick Ratio | 0.0 | 0.2 | 0.4 | 1.0 | 2.0 | 0.8 | 0.6 | 0.8 | 1.1 | 2.1 | 6.3 | · | |
| Debt / Equity | -0.2 | -0.1 | -0.1 | -0.2 | 0.4 | -0.1 | -0.1 | -0.1 | -2.2 | -3.3 | 1.6 | · | |
| LT Debt / Equity | 0.0 | -0.1 | -0.1 | -0.2 | 0.4 | -0.1 | -0.1 | -0.1 | -1.9 | -3.3 | 1.6 | · |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.4 | 0.2 | 0.9 | 0.5 | 1.0 | 0.3 | 0.3 | 0.1 | 0.2 | · | |
| Receivables Turnover | 102.1 | 7.9 | 10.9 | 46.0 | 221.1 | 10.1 | 17.4 | 35.5 | 6.9 | 2.1 | 4.8 | · |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-7.68 | · | · | · | · | · | · | · | · | · | · | · | |
| Revenue / Share | $3.84 | $4.82 | $436.77 | $347.92 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-2.60 | $-7.37 | $-626.46 | $-622.46 | · | · | · | · | · | · | · | · | |
| Cash / Share | $0.08 | · | · | · | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 | $-1.05 | $-0.81 | · | $-1.13 | $-1.13 | $-1.13 | $-1.13 |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 10.4% | -33.8% | 59.5% | -66.8% | 235.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.2% | -29.5% | 21.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 5.3% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $114M | $103M | $156M | $98M | $296M | $88M | $150M | $37M | $43M | $23M | $25M | $7M | |
| Net Income TTM | $-3M | $-232M | $-257M | $-231M | $-29M | $-183M | $-112M | $-162M | $-121M | $-127M | $-88M | $-42M | |
| Market Cap | $111M | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $153M | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | · | -0.3 | -1.2 | -3.0 | -574.5 | -59.4 | -98.6 | · | -56.6 | -71.6 | -78.9 | -69.0 | |
| P/S | 1.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | -0.4 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | -1.4 | · | · | · | · | · | · | · | · | · | · | · | |
| P / FCF | -1.4 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -7.6 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | -2.0 | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 1.3 | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 0.00% | -386.5% | -82.8% | -33.2% | -0.17% | -1.7% | -1.0% | · | -1.8% | -1.4% | -1.3% | -1.5% |
Demonstração de Resultados
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35M | $34M | $34M | $30M | $26M | $24M | $27M | $25M | $24M | $28M | $84M | $24M | $25M | $23M | $28M | $23M | |
| Cost of Revenue | $0 | $0 | $0 | $642.0K | $243.0K | $137.0K | $118.0K | $146.0K | $115.0K | $107.0K | $260.0K | $303.0K | $254.0K | $2M | $8M | $308.0K | |
| R&D Expense | $15M | $12M | $8M | $24M | $27M | $22M | $34M | $41M | $37M | $44M | $67M | $51M | $59M | $57M | $53M | $46M | |
| SG&A Expense | $8M | $7M | $12M | $11M | $16M | $16M | $21M | $17M | $17M | $17M | $21M | $19M | $20M | $18M | $25M | $18M | |
| Operating Expenses | $23M | $19M | · | · | $42M | $37M | · | · | · | · | · | · | · | · | · | · | |
| Operating Income | $11M | $15M | $14M | $-5M | $-17M | $-13M | $-26M | $-32M | $-30M | $-33M | $-4M | $-46M | $-55M | $-54M | $-58M | $-42M | |
| Interest Income | $121.0K | $21.0K | $29.0K | $74.0K | $54.0K | $188.0K | $429.0K | $1M | $539.0K | $808.0K | · | · | · | · | · | · | |
| Other Non-op | $3M | $39M | $-9M | $82M | $-12.0K | $-264.0K | $-224.0K | $19.0K | $7M | $-1M | $-201.0K | $442.0K | $-244.0K | $40.0K | $980.0K | $537.0K | |
| Net Income | $-567.0K | $39M | $-11M | $64M | $-30M | $-26M | $-47M | $-67M | $-55M | $-63M | $-49M | $-65M | $-73M | $-71M | $-74M | $-57M | |
| EPS (Basic) | $-0.01 | $1.03 | $0.03 | $2.00 | $-1.00 | $-1.03 | $-1.95 | $-3.08 | $-2.52 | $-3.04 | $-2.22 | $-3.29 | $-3.93 | $-4.31 | $-15.09 | $-0.19 | |
| EPS (Diluted) | $-0.01 | $1.02 | $0.09 | $1.94 | $-1.00 | $-1.03 | $-1.95 | $-3.08 | $-2.52 | $-3.04 | $-2.22 | $-3.29 | $-3.93 | $-4.31 | $-15.09 | $-0.19 | |
| Shares (Basic) | 41,338,000 | 37,941,000 | · | 31,886,000 | 28,117,000 | 24,469,000 | · | 21,550,000 | 21,062,000 | 20,368,000 | · | 18,908,000 | 17,569,000 | 15,855,000 | · | 286,854 | |
| Shares (Diluted) | 41,338,000 | 38,285,000 | · | 32,858,000 | 28,117,000 | 24,469,000 | · | 21,550,000 | 21,062,000 | 20,368,000 | · | 18,908,000 | 17,569,000 | 15,855,000 | · | 286,854 | |
| EBITDA | $11M | $15M | · | $-5M | $-17M | $-13M | · | $-32M | $-30M | $-33M | · | $-46M | $-55M | $-54M | · | $-42M |
Balanço Patrimonial
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $35M | $3M | $3M | $10M | $18M | $40M | $45M | $94M | $53M | $76M | $106M | $143M | $165M | $179M | $208M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | $15M | $24M | · | $10M | |
| Receivables | $15M | $7M | $2M | $538.0K | $709.0K | $354.0K | $407.0K | $207.0K | $719.0K | $476.0K | · | $1M | $1M | $1M | · | $9M | |
| Prepaid Expense | $3M | $4M | $785.0K | $885.0K | $1M | $2M | $2M | $2M | $2M | $4M | · | $16M | $9M | $11M | · | $22M | |
| Other Current Assets | $2M | $2M | $1M | $1M | $2M | $2M | $2M | $3M | $3M | $3M | · | $2M | $3M | $4M | · | $2M | |
| Current Assets | $79M | $95M | $133M | $134M | $13M | $23M | $46M | $50M | $100M | $60M | · | $126M | $171M | $206M | · | $251M | |
| PP&E (Net) | $14M | $15M | $15M | $16M | $113M | $117M | $120M | $124M | $128M | $130M | · | $140M | $143M | $140M | · | $101M | |
| PP&E (Gross) | · | · | $63M | · | · | · | $193M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $48M | $48M | $47M | $47M | $75M | $76M | $73M | $71M | $68M | $65M | · | $61M | $58M | $56M | · | $53M | |
| Goodwill | $24M | $24M | $24M | $24M | $24M | $24M | $24M | $25M | $25M | $25M | · | $25M | $25M | $26M | · | $24M | |
| Intangibles | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | · | $4M | $5M | $6M | · | $7M | |
| Other Non-current Assets | $4M | $3M | $3M | $3M | $5M | $6M | $6M | $7M | $7M | $8M | · | $11M | $9M | $4M | · | $8M | |
| Total Assets | $173M | $186M | $227M | $234M | $185M | $200M | $226M | $238M | $292M | $257M | · | $335M | $384M | $413M | · | $429M | |
| Accounts Payable | $59M | $71M | $83M | $85M | $74M | $64M | $61M | $46M | $51M | $51M | · | $41M | $52M | $47M | · | $40M | |
| Accrued Liabilities | $28M | $37M | $34M | $32M | $39M | $36M | $35M | $37M | $41M | $41M | · | $38M | $30M | $33M | · | $29M | |
| Current Liabilities | $232M | $249M | $323M | $287M | $235M | $208M | $221M | $271M | $271M | $256M | · | $198M | $204M | $191M | · | $173M | |
| Capital Leases | $10M | $10M | $10M | $10M | $53M | $54M | $55M | $55M | $56M | $62M | · | $63M | $62M | $63M | · | $64M | |
| Other Non-current Liabilities | $247.0K | $247.0K | $259.0K | $376.0K | $752.0K | $761.0K | $738.0K | $777.0K | $1M | $3M | · | $8M | $11M | $14M | · | $1M | |
| Long-term Debt | $30M | $30M | $45M | $34M | $34M | $34M | $33M | $13M | $13M | $14M | · | $13M | $13M | $14M | · | · | |
| Total Debt | $30M | $30M | · | $34M | $34M | $34M | · | $13M | $13M | $14M | · | $13M | $13M | $14M | · | $13M | |
| Common Stock | $427.0K | $385.0K | $353.0K | $329.0K | $300.0K | $266.0K | $236.0K | $217.0K | $211.0K | $210.0K | · | $4M | $4M | $3M | · | $3M | |
| Paid-in Capital | $1.95B | $1.92B | $1.91B | $1.90B | $1.88B | $1.87B | $1.86B | $1.85B | $1.83B | $1.82B | · | $1.78B | $1.75B | $1.72B | · | $1.61B | |
| Retained Earnings | $-2.14B | $-2.14B | $-2.18B | $-2.17B | $-2.24B | $-2.21B | $-2.18B | $-2.14B | $-2.07B | $-2.02B | · | $-1.91B | $-1.85B | $-1.78B | · | $-1.64B | |
| AOCI | $-450.0K | $-437.0K | $-439.0K | $-2M | $-2M | $-1M | $-1M | $-1M | $-1M | $-1M | · | $-1M | $-717.0K | $917.0K | · | $644.0K | |
| Stockholders' Equity | $-199M | $-221M | $-271M | $-274M | $-355M | $-342M | $-326M | $-292M | $-241M | $-201M | · | $-129M | $-93M | $-59M | · | $-20M | |
| Liabilities + Equity | $173M | $186M | $227M | $234M | $185M | $200M | $226M | $238M | $292M | $257M | · | $335M | $384M | $413M | · | $429M | |
| Shares Outstanding | 42,615,618 | 38,521,761 | 35,320,397 | 32,814,429 | 30,004,430 | 26,563,545 | 23,634,670 | 21,685,192 | 21,126,226 | 20,994,143 | · | · | · | · | · | · |
Fluxo de Caixa
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $517.0K | $583.0K | $597.0K | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $3M | $3M | $3M | $2M | $2M | |
| Stock-based Comp | $4M | $1M | $3M | $3M | $4M | $3M | $5M | $5M | $4M | $4M | $5M | $6M | $6M | $5M | $4M | $4M | |
| Operating Cash Flow | $-31M | $-36M | $-17M | $-15M | $-20M | $-26M | $-29M | $-53M | $-38M | $-38M | $-40M | $-65M | $-60M | $-59M | $-47M | $-32M | |
| CapEx | $0 | $0 | $0 | $0 | $1.0K | $5.0K | $73.0K | $7.0K | $461.0K | $35.0K | $223.0K | $3M | $4M | $2M | $14M | $16M | |
| Investing Cash Flow | $267.0K | $69M | $780.0K | $76.0K | $281.0K | $57.0K | $-21.0K | $56.0K | $-237.0K | $229.0K | $3M | $12M | $517.0K | $-11M | $-6M | $-16M | |
| Net Debt Issued | · | $-8M | · | · | · | $-2M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $15M | $-993.0K | $15M | $7M | $11M | $4M | $24M | $5M | $79M | $15M | $7M | $18M | $38M | $56M | $24M | $28M | |
| Net Change in Cash | $-16M | $32M | $-460.0K | $-8M | $-9M | $-22M | $-4M | $-49M | $41M | $-23M | $-30M | $-36M | $-22M | $-14M | $-30M | $-20M | |
| Free Cash Flow | · | $-36M | · | · | · | $-26M | · | · | · | $-38M | · | · | · | $-60M | · | · |
Lucratividade
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 32.7% | 44.6% | · | -15.0% | -65.0% | -55.3% | · | -125.4% | -128.4% | -117.4% | · | -190.6% | -216.1% | -237.3% | · | -182.9% | |
| Net Margin | -1.6% | 116.2% | · | 211.4% | -116.8% | -109.6% | · | -267.7% | -233.1% | -226.6% | · | -265.4% | -290.3% | -309.6% | · | -249.1% | |
| EBITDA Margin | 32.7% | 44.6% | · | -15.0% | -65.0% | -55.3% | · | -125.4% | -128.4% | -117.4% | · | -190.6% | -216.1% | -237.3% | · | -182.9% | |
| ROA | -0.32% | 20.3% | · | 27.1% | -12.6% | -11.6% | · | -23.4% | -16.2% | -19.0% | · | -16.9% | -17.5% | -16.6% | · | -13.1% | |
| ROE | 0.20% | -13.9% | · | -22.6% | 10.1% | 9.7% | · | 31.9% | 32.8% | 48.8% | · | 86.3% | 163.6% | 331.1% | · | -528.3% |
Liquidez e Solvência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.3 | 0.4 | · | 0.5 | 0.1 | 0.1 | · | 0.2 | 0.4 | 0.2 | · | 0.6 | 0.8 | 1.1 | · | 1.5 | |
| Quick Ratio | 0.1 | 0.2 | · | 0.0 | 0.0 | 0.1 | · | 0.2 | 0.3 | 0.2 | · | 0.5 | 0.8 | 1.0 | · | 1.3 | |
| Debt / Equity | -0.2 | -0.1 | · | -0.1 | -0.1 | -0.1 | · | -0.0 | -0.1 | -0.1 | · | -0.1 | -0.1 | -0.2 | · | -0.7 | |
| LT Debt / Equity | · | · | · | -0.1 | -0.1 | -0.1 | · | 0.0 | 0.0 | 0.0 | · | -0.1 | -0.1 | -0.2 | · | · |
Eficiência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 4.5 | 9.8 | · | 81.2 | 36.0 | 58.0 | · | 40.6 | 22.8 | 29.6 | · | 4.9 | 2.5 | 16.9 | · | 1.5 |
Por Ação
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-4.67 | $-5.74 | · | $-8.35 | $-11.82 | $-12.87 | · | $-13.48 | $-11.42 | $-9.59 | · | · | · | · | · | · | |
| Revenue / Share | $0.83 | $0.88 | · | $0.92 | $0.91 | $0.98 | · | $1.17 | $1.12 | $1.38 | · | $64.30 | $71.99 | $72.22 | · | $79.39 | |
| Cash Flow / Share | · | $-0.94 | · | · | · | $-1.05 | · | · | · | $-1.88 | · | · | · | $-184.56 | · | · | |
| Cash / Share | $0.44 | $0.91 | · | $0.11 | $0.32 | $0.70 | · | $2.07 | $4.44 | $2.52 | · | · | · | · | · | · | |
| EPS (TTM) | $3.04 | $2.05 | · | $-2.04 | $-7.06 | $-8.58 | · | $-10.86 | $-11.07 | $-12.48 | · | $-26.62 | $-23.52 | $-19.76 | · | $-0.84 |
Avaliação (TTM)
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $133M | $124M | · | $107M | $102M | $100M | · | $160M | $160M | $161M | · | $101M | $99M | $95M | · | $90M | |
| Net Income TTM | $92M | $62M | · | $-39M | $-170M | $-195M | · | $-234M | $-231M | $-250M | · | $-283M | $-275M | $-251M | · | $-224M | |
| Market Cap | $130M | $129M | · | $126M | $137M | $40M | · | $119M | $354M | $244M | · | · | · | · | · | · | |
| Enterprise Value | $142M | $124M | · | $157M | $161M | $55M | · | $87M | $274M | $204M | · | · | · | · | · | · | |
| P/E | 1.0 | 1.6 | · | -1.9 | -0.6 | -0.2 | · | -0.5 | -1.5 | -0.9 | · | -0.8 | -1.4 | -1.5 | · | -47.9 | |
| P/S | 1.0 | 1.0 | · | 1.2 | 1.3 | 0.4 | · | 0.7 | 2.2 | 1.5 | · | · | · | · | · | · | |
| P/B | -0.7 | -0.6 | · | -0.5 | -0.4 | -0.1 | · | -0.4 | -1.5 | -1.2 | · | · | · | · | · | · | |
| P / Cash Flow | · | -3.6 | · | · | · | -1.6 | · | · | · | -6.4 | · | · | · | · | · | · | |
| EV / Revenue | 1.1 | 1.0 | · | 1.5 | 1.6 | 0.6 | · | 0.5 | 1.7 | 1.3 | · | · | · | · | · | · | |
| Earnings Yield | 99.4% | 61.4% | · | -53.0% | -154.5% | -568.2% | · | -198.2% | -66.1% | -107.6% | · | -117.8% | -73.5% | -66.2% | · | -2.1% |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Receita | $114M | $103M | $156M | $98M | $296M |
| Margem Operacional % | -17.7% | -116.4% | -102.1% | -183.0% | 8.7% |
| Lucro líquido | $-3M | $-232M | $-257M | $-231M | $-29M |
| EPS Diluído | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | -0.2 | -0.1 | -0.1 | -0.2 | 0.4 |
| Índice de liquidez corrente | 0.4 | 0.2 | 0.4 | 1.1 | 2.1 |
| Índice de Liquidez Seca | 0.0 | 0.2 | 0.4 | 1.0 | 2.0 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $-77M | $-159M | $-234M | $-228M | $-24M |
Investidores institucionais (13F) 116 declarantes · $53.2M total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 32 (+18 vs trimestre anterior) | 14 (-3 vs trimestre anterior) | 33 (+15 vs trimestre anterior) | 21 (-12 vs trimestre anterior) | +5.0M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| VANGUARD GROUP INC | $8.888.511 | 2.830.736 | 16,72% | Ações |
| BlackRock, Inc. | $7.848.543 | 2.564.884 | 14,76% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.128.854 | 1.676.096 | 9,65% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $4.368.416 | 1.427.587 | 8,22% | Ações |
| Siren, L.L.C. | $3.256.605 | 1.064.250 | 6,12% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $3.168.086 | 1.035.040 | 5,96% | Ações |
| MACKENZIE FINANCIAL CORP | $2.185.376 | 714.175 | 4,11% | Ações |
| GOLDMAN SACHS GROUP INC | $1.372.052 | 448.383 | 2,58% | Ações |
| MARSHALL WACE, LLP | $1.345.239 | 439.621 | 2,53% | Ações |
| RAYMOND JAMES FINANCIAL INC | $1.316.038 | 430.078 | 2,48% | Ações |
| GLOBEFLEX CAPITAL L P | $1.280.858 | 418.581 | 2,41% | Ações |
| STATE STREET CORP | $1.261.892 | 412.383 | 2,37% | Ações |
| Man Group plc | $1.041.701 | 340.425 | 1,96% | Ações |
| NORTHERN TRUST CORP | $961.000 | 314.052 | 1,81% | Ações |
| Connor, Clark & Lunn Investment Management Ltd. | $948.707 | 310.035 | 1,78% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $831.139 | 271.614 | 1,56% | Ações |
| MORGAN STANLEY | $801.929 | 262.068 | 1,51% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $698.739 | 228.346 | 1,31% | Ações |
| PANAGORA ASSET MANAGEMENT INC | $549.542 | 179.589 | 1,03% | Ações |
| Susquehanna Portfolio Strategies, LLC | $485.735 | 158.737 | 0,91% | Ações |
| Cubist Systematic Strategies, LLC | $393.512 | 102.211 | 0,74% | Ações |
| Jump Financial, LLC | $318.182 | 103.981 | 0,60% | Ações |
| Bank of New York Mellon Corp | $311.424 | 101.773 | 0,59% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $304.140 | 99.392 | 0,57% | Ações |
| TWO SIGMA INVESTMENTS, LP | $301.976 | 98.685 | 0,57% | Ações |
| STRS OHIO | $235.314 | 76.900 | 0,44% | Ações |
| CANADA PENSION PLAN INVESTMENT BOARD | $205.326 | 67.100 | 0,39% | Ações |
| BANK OF AMERICA CORP /DE/ | $159.157 | 52.012 | 0,30% | Ações |
| Invesco Ltd. | $155.870 | 50.938 | 0,29% | Ações |
| WELLS FARGO & COMPANY/MN | $132.245 | 43.217 | 0,25% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $128.569 | 42.016 | 0,24% | Ações |
| Avestar Capital, LLC | $125.460 | 41.000 | 0,24% | Ações |
| DEUTSCHE BANK AG\ | $119.046 | 38.904 | 0,22% | Ações |
| TWO SIGMA ADVISERS, LP | $107.529 | 34.245 | 0,20% | Ações |
| Claro Advisors Inc. | $102.051 | 33.350 | 0,19% | Ações |
| XTX Topco Ltd | $96.849 | 31.650 | 0,18% | Ações |
| CITADEL ADVISORS LLC | $90.270 | 29.500 | 0,17% | Opção de compra |
| RHUMBLINE ADVISERS | $90.226 | 29.488 | 0,17% | Ações |
| CAPTRUST FINANCIAL ADVISORS | $88.654 | 28.972 | 0,17% | Ações |
| Engineers Gate Manager LP | $85.092 | 27.808 | 0,16% | Ações |
| CITIGROUP INC | $84.768 | 27.702 | 0,16% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $77.418 | 25.300 | 0,15% | Opção de compra |
| LPL Financial LLC | $73.948 | 24.166 | 0,14% | Ações |
| Key Client Fiduciary Advisors, LLC | $73.823 | 24.125 | 0,14% | Ações |
| OSAIC HOLDINGS, INC. | $71.786 | 23.460 | 0,14% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $67.002 | 21.896 | 0,13% | Ações |
| WOLVERINE TRADING, LLC | $63.282 | 15.900 | 0,12% | Opção de compra |
| CITADEL ADVISORS LLC | $62.730 | 20.500 | 0,12% | Opção de venda |
| PRELUDE CAPITAL MANAGEMENT, LLC | $60.469 | 19.761 | 0,11% | Ações |
| PRUDENTIAL FINANCIAL INC | $59.395 | 19.410 | 0,11% | Ações |
Ativistas e proprietários de 5%+ 5 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| ZYNEXT VENTURES USA LLC, ZYNEXT VENTURES PTE LTD, ZYDUS LIFESCIENCES LTD | 23 de Janeiro de 2026 | 5,90% | Declaração inicial | · | SEC |
| Agenus Inc. (“Agenus”) ×3 declarações | 26 de Maio de 2023 | · | Declaração inicial | Investimento passivo | SEC |
| Garo H. Armen | 22 de Janeiro de 2008 | · | Declaração inicial | Investimento passivo | SEC |
| Brad M. Kelley 2) ×4 declarações | 27 de Fevereiro de 2003 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada | 1 de Maio de 2001 | · | Declaração inicial | M&A / venda | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Executivos da empresa 46 insiders · 7 diretores · 7 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Jeff D Clark | Chief Financial Officer | 18 de Fevereiro de 2004 A | · | 0 | 0 | $0 |
| Austin Charette | Principal Accounting Officer | 24 de Abril de 2026 A | · | 0 | 0 | $0 |
| Christine M Klaskin | PFO & PAO | 18 de Junho de 2025 A | 23.478 | 0 | 0 | $0 |
| Evan Kearns | VP and General Counsel | 17 de Dezembro de 2020 A | · | 0 | 0 | $0 |
| Christian Cortis | Chief Strategy Officer | 23 de Julho de 2019 A | · | 0 | 0 | $0 |
| Alex Duncan | Chief Technology Officer | 23 de Julho de 2019 A | 21.026 | 0 | 0 | $0 |
| Neal Gordon | SrVP, Manufacturing Operations | 18 de Fevereiro de 2004 A | · | 0 | 0 | $0 |
| Timothy Wright | Conselheiro | 1 de Outubro de 2026 A | 50.391 | 0 | 0 | $0 |
| Thomas L Harrison | Conselheiro | 1 de Outubro de 2026 A | 51.988 | 0 | 0 | $0 |
| Marco Tullio Marcucci | Conselheiro | 5 de Agosto de 2026 A | · | 0 | 0 | $0 |
| Ulf Wiinberg | Conselheiro | 1 de Outubro de 2024 A | 124.063 | 0 | 0 | $0 |
| Allison M Jeynes-Ellis | Conselheiro | 5 de Fevereiro de 2024 A | 66.176 | 0 | 0 | $0 |
| Wadih Jordan | Conselheiro | 3 de Outubro de 2022 A | · | 0 | 0 | $0 |
| Paul N Clark | Conselheiro | 1 de Abril de 2021 A | · | 0 | 0 | $0 |
| INCYTE CORP | Detentor de 10% | 17 de Junho de 2020 S | 16.972.968 | 0 | 0 | $0 |
| Brad M Kelley | Detentor de 10% | 24 de Setembro de 2003 P | 5.546.740 | 0 | 0 | $0 |
| Garo H Armen | · | 10 de Agosto de 2026 A | 371.108 | 0 | 0 | $0 |
| Steven J O'Day | · | 5 de Agosto de 2026 A | 57.116 | 0 | 0 | $0 |
| Susan B Hirsch | · | 5 de Agosto de 2026 A | 108.725 | 0 | 0 | $0 |
| Jennifer Buell | · | 5 de Agosto de 2026 A | 19.738 | 0 | 0 | $0 |
| Brian Corvese | · | 5 de Agosto de 2026 A | 92.085 | 0 | 0 | $0 |
| Adam Krauss | · | 15 de Junho de 2021 A | · | 0 | 0 | $0 |
| Shalini Sharp | · | 21 de Junho de 2018 A | 104.270 | 0 | 0 | $0 |
| Ozer Baysal | · | 20 de Junho de 2018 A | 58.790 | 0 | 0 | $0 |
| Karen Valentine | · | 20 de Junho de 2018 A | 101.521 | 0 | 0 | $0 |
| Jean-Marie Cuillerot | · | 31 de Março de 2017 A | · | 0 | 0 | $0 |
| Robert Benjamin Stein | · | 31 de Março de 2017 A | 20.986 | 0 | 0 | $0 |
| Shahzad Malik | · | 15 de Junho de 2016 A | 1.587.302 | 0 | 0 | $0 |
| Charles Evan Ballantyne | · | 14 de Junho de 2016 A | 24.795 | 0 | 0 | $0 |
| Tom Dechaene | · | 4 de Janeiro de 2016 A | · | 0 | 0 | $0 |
| Kerry Wentworth | · | 26 de Fevereiro de 2014 S | 57.410 | 0 | 0 | $0 |
| John Hatsopoulos | · | 3 de Outubro de 2011 A | 65.000 | 0 | 0 | $0 |
| ROTHWELL TIMOTHY G | · | 3 de Outubro de 2011 J | 7.389 | 0 | 0 | $0 |
| Hyam Levitsky | · | 1 de Julho de 2011 A | 15.376 | 0 | 0 | $0 |
| Peter Thornton | · | 5 de Junho de 2008 A | 5.000 | 0 | 0 | $0 |
| Eisen Margaret | · | 5 de Junho de 2008 A | 20.000 | 0 | 0 | $0 |
| AFEYAN NOUBAR | · | 2 de Abril de 2007 A | 0 | 0 | 0 | $0 |
| ATLEE FRANK V III | · | 2 de Abril de 2007 A | 0 | 0 | 0 | $0 |
| Pramod Srivastava | · | 9 de Fevereiro de 2007 S | 1.610 | 0 | 0 | $0 |
| Roman Chicz | · | 5 de Janeiro de 2007 A | · | 0 | 0 | $0 |
| Mark Kessel | · | 2 de Outubro de 2006 A | · | 0 | 0 | $0 |
| Bruce Leicher | · | 15 de Setembro de 2006 A | · | 0 | 0 | $0 |
| Alastair Jj Wood | · | 15 de Junho de 2006 A | · | 0 | 0 | $0 |
| Gamil De Chadarevian | · | 28 de Fevereiro de 2006 M | 88.610 | 0 | 0 | $0 |
| Renu Gupta | · | 24 de Fevereiro de 2006 A | · | 0 | 0 | $0 |
| Russell Herndon | · | 8 de Dezembro de 2004 A | · | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 12 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,57% | 15.754 SH | 2 de Outubro de 2026 | Diário |
| IWC · iShares Trust | 0,06% | 134.978 SH | 11 de Setembro de 2026 | Diário |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,01% | 29.536 SH | 19 de Agosto de 2026 | Diário |
| RSSL · Global X Funds | 0,01% | 19.052 NS | 31 de Julho de 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 1.003.811 SH | 11 de Setembro de 2026 | Diário |
| IWO · iShares Trust | 0,01% | 137.756 SH | 11 de Setembro de 2026 | Diário |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 485.158 SH | 19 de Agosto de 2026 | Diário |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.159.672 SH | 19 de Agosto de 2026 | Diário |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,00% | 230.345 SH | 19 de Agosto de 2026 | Diário |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 6.460 SH | 19 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 5.125 SH | 19 de Agosto de 2026 | Diário |
| IWN · iShares Trust | · | 310.686 SH | 11 de Setembro de 2026 | Diário |
AGEN Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
Preço-alvo de 12 meses
3 analistas · 2026-10-04Alvo médio $26.33 +215,0%
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| AGEN | $111M | · | 10.4% | -2.7% | 1.0% | · |
| EDIT | $201M | -1.1 | 25.4% | -395.0% | -688.8% | · |
| GALT | $271M | -8.7 | · | · | 25.0% | · |
| IRD | $140M | -2.5 | 29.1% | -349.3% | -302.2% | · |
| XFOR | $364M | -2.1 | 150.0% | -1218.5% | -83.2% | · |
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | · |
| ARCT | $174M | -2.6 | -46.1% | -80.2% | -29.6% | · |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.